Terms: = Bone cancer AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Prognosis
274 results:
1. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
[No Abstract] [Full Text] [Related]
2. Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in mds and CMML progression to sAML.
Bauer M; Jäkel N; Wilfer A; Haak A; Eszlinger M; Kelemen K; Haemmerle M; Al-Ali HK; Seliger B; Wickenhauser C
Oncoimmunology; 2024; 13(1):2323212. PubMed ID: 38481730
[TBL] [Abstract] [Full Text] [Related]
3. TP53 in mds and AML: Biological and clinical advances.
Zhao Y; Chen W; Yu J; Pei S; Zhang Q; Shi J; Huang H; Zhao Y
Cancer Lett; 2024 Apr; 588():216767. PubMed ID: 38417666
[TBL] [Abstract] [Full Text] [Related]
4. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Nabergoj M; Eikema DJ; Koster L; Platzbecker U; Sockel K; Finke J; Kröger N; Forcade E; Nagler A; Eder M; Tischer J; Broers AEC; Kuball J; Wilson KMO; Hunault-Berger M; Collin M; Russo D; Corral LL; Helbig G; Mussetti A; Scheid C; Gurnari C; Raj K; Drozd-Sokolowska J; Yakoub-Agha I; Robin M; McLornan DP
Bone Marrow Transplant; 2024 Mar; 59(3):395-402. PubMed ID: 38195984
[TBL] [Abstract] [Full Text] [Related]
5. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract] [Full Text] [Related]
6. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, mds): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
[TBL] [Abstract] [Full Text] [Related]
7. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.
DiGennaro J; Sallman DA
Acta Haematol; 2024; 147(2):175-185. PubMed ID: 38052186
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
9. Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Alhajahjeh A; Nazha A
Curr Hematol Malig Rep; 2024 Feb; 19(1):9-17. PubMed ID: 37999872
[TBL] [Abstract] [Full Text] [Related]
10. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
[TBL] [Abstract] [Full Text] [Related]
11. Morphologic Characteristics of Myelodysplastic Syndromes.
Yuen LD; Hasserjian RP
Clin Lab Med; 2023 Dec; 43(4):577-596. PubMed ID: 37865504
[TBL] [Abstract] [Full Text] [Related]
12. [Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first allogeneic transplant].
Zhao YQ; Song YZ; Li ZH; Yang F; Xu T; Li FF; Yang DF; Wu T
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):465-471. PubMed ID: 37550201
[No Abstract] [Full Text] [Related]
13. Role of IL8 in myeloid malignancies.
Ramachandra N; Gupta M; Schwartz L; Todorova T; Shastri A; Will B; Steidl U; Verma A
Leuk Lymphoma; 2023; 64(11):1742-1751. PubMed ID: 37467070
[TBL] [Abstract] [Full Text] [Related]
14. [mds & CMML: Diagnostic and classification].
Wagner-Ballon O; Kosmider O
Bull Cancer; 2023 Nov; 110(11):1106-1115. PubMed ID: 37453834
[TBL] [Abstract] [Full Text] [Related]
15. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
Guastafierro V; Ubezio M; Manes N; Milanesi C; Della Porta M; Bonometti A
Leuk Lymphoma; 2023 Sep; 64(9):1566-1573. PubMed ID: 37395413
[TBL] [Abstract] [Full Text] [Related]
16. Therapy-related myelodysplastic syndromes in the genomics era.
Renneville A; Bernard E; Micol JB
Bull Cancer; 2023 Nov; 110(11):1129-1140. PubMed ID: 37391357
[TBL] [Abstract] [Full Text] [Related]
17.
de Carvalho LGA; Komoto TT; Moreno DA; Goes JVC; de Oliveira RTG; de Lima Melo MM; Roa MEGV; Gonçalves PG; Montefusco-Pereira CV; Pinheiro RF; Ribeiro Junior HL
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373211
[TBL] [Abstract] [Full Text] [Related]
18. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
[TBL] [Abstract] [Full Text] [Related]
19. Hypoplastic form of myelodysplastic neoplasm.
Votavová H; Lenertová Z; Votava T; Beličková M
Klin Onkol; 2023; 36(3):206-214. PubMed ID: 37353349
[TBL] [Abstract] [Full Text] [Related]
20. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract] [Full Text] [Related]
[Next]
